Figure 3. Phosphorylated p70S6K best predicted ketamine response. The phosphorylated p70S6K marker had an AUC of 0.80 (confidence interval: 0.54-0.97) for predicting ketamine response. An optimal ...
Oncotarget published "High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC" which reported that the aim of this study was therefore to define ...
A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. New soft tissue sarcoma (STS) transcriptomic clusters to ...
San Francisco–based Aeovian Pharmaceuticals has raised $37 million in series A financing to develop a small-molecule drug candidate that inhibits a protein complex called mammalian target of rapamycin ...
- Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase 2 clinical trial - Round co-led by Luma Group and CTI ...
Work at Apertor Pharmaceuticals Inc. has led to the preparation of new hetero-bifunctional compounds acting as mTOR complex 1 (mTORC1) inhibitors potentially useful for the treatment of cancer.
Panel A shows how insulin and insulin-like growth factor-1 (IGF-1) effect protein anabolism by signaling through their receptors (IR and IGF1R, respectively). This signaling results in the activation ...
The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results